Mechanistic Exploration Of The “Kidney-Nourishing And Blood-Activating” Method For Diabetic Nephropathy From The Perspective Of PANoptosis
Apr 10, 2026
Abstract
This article examines the mechanistic relationship between PANoptosis and the traditional Chinese medicine (TCM) strategy known as the kidney-nourishing and blood-activating method in the context of diabetic nephropathy (DN) (also referred to as diabetic kidney disease, DKD). PANoptosis, an emerging form of inflammatory programmed cell death integrating apoptosis, pyroptosis, and necroptosis, has been recognized as a key driver of DN pathology, including podocyte injury, glomerulosclerosis, and tubulointerstitial fibrosis. The TCM core pathogenesis of DN-often summarized as "kidney deficiency with blood stasis"-has long guided clinical prescription patterns, yet its modern biological correlates remain incompletely clarified.
We systematically review the triggers of PANoptosis in DN (e.g., hyperglycemia, lipotoxicity) and the core execution pathways, with a particular focus on activation mechanisms of the NLRP3 inflammasome (NOD-like receptor family pyrin domain containing 3). Building on this, we further argue that (1) the "root deficiency" pattern (e.g., spleen–kidney deficiency) corresponds functionally to mitochondrial energy metabolic dysfunction, and (2) the "branch excess" pattern (e.g., phlegm–stasis interlocking) aligns morphologically and pathophysiologically with NLRP3-driven inflammatory storms after inflammasome activation.
We propose the novel, testable hypothesis that the kidney-nourishing and blood-activating method may exert therapeutic effects by modulating PANoptosis in DN. As a representative herb pair, Astragalus (Huangqi)–Salvia miltiorrhiza (Danshen) is highlighted, and evidence for major bioactive constituents (e.g., astragaloside IV, tanshinone IIA) is summarized. These compounds may act synergistically via multi-target mechanisms such as restoring mitochondrial function, reducing reactive oxygen species (ROS), and directly interfering with NLRP3 inflammasome assembly and activation, ultimately suppressing PANoptosis.
In addition, given growing real-world demand for herbal extracts for diabetes-related kidney health (e.g., "Herb Extract for Diabetes," "botanical kidney support," "diabetes kidney support supplement"), we discuss how mechanistic hypotheses can be translated into verifiable research endpoints while maintaining scientific rigor and clinical safety. We also introduce Cistanche (Cistanche tubulosa)-a traditional "kidney-tonifying" botanical widely used in TCM and increasingly commercialized as an extract-into the mechanistic discussion as a candidate supportive herb, based on its reported constituents (e.g., echinacoside, verbascoside, flavonoids) and suggested antioxidative/anti-fatigue and kidney-supportive applications. WECISTANCHE-CistancheKidneyPage
Keywords: diabetic nephropathy; diabetic kidney disease; PANoptosis; NLRP3 inflammasome; kidney-nourishing and blood-activating method; Astragalus–Danshen; Herb Extract for Diabetes; Cistanche tubulosa extract
Cistanche Extract Benefits For Improving Kidney Function

Cistanche High Content Extract Supplements Sale In China


Supportive Service Of Wecistanche-For more details about cooperation
Email:wallence.suen@wecistanche.com
1. PANoptosis as a Key Driver of Renal Injury in Diabetic Nephropathy
Diabetic nephropathy is among the most severe microvascular complications of diabetes. Approximately one-third of individuals with diabetes eventually develop DN, and it has become a major cause of end-stage renal disease and premature mortality, accounting for more than half of dialysis or kidney transplant cases in some cohorts. [1–2]
A pathological hallmark of DN is the progressive loss of renal intrinsic cells, particularly glomerular podocytes and renal tubular epithelial cells, culminating in fibrosis and proteinuria. Apoptosis was traditionally considered the predominant mode of cell death; however, recent findings suggest that PANoptosis, a more complex programmed cell death network, serves as a crucial driver of DN's accelerated progression. Unlike a single-pathway death mode, PANoptosis features the co-activation of apoptosis, pyroptosis, and necroptosis, resulting in a highly inflammatory and often irreversible phenotype that can amplify renal structural damage.
1.1 Experimental evidence supports synergistic activation of PANoptosis in DN renal tissue
PANoptosis is not merely the independent action of three cell-death pathways; rather, it is coordinated through the PANoptosome complex, which integrates:
Caspase-mediated apoptosis,
Gasdermin D (GSDMD)-mediated pyroptosis, and
RIPK3/MLKL-mediated necroptosis. [3–6]
In DN patient samples and experimental models, single-cell RNA sequencing has revealed significant upregulation of key factors in podocytes, including TNFSF10 (TRAIL) and TNFRSF10B (DR5). This upregulation correlates with increased susceptibility to podocyte PANoptosis (co-activation of apoptosis, pyroptosis, and necroptosis). Experimental interventions-such as podocyte-specific deletion of TNFSF10 or TNFRSF10B-can substantially alleviate podocyte injury, glomerular damage, and proteinuria in obese diabetic mouse models. Moreover, treatment with soluble TRAIL has been shown to modulate related pathways, further supporting a causal role for PANoptosis in podocyte loss and DN progression. [7]

1.2 The NLRP3 inflammasome is a central hub mediating hyperglycemia-induced PANoptosis
In DN, persistent hyperglycemia and chronic inflammation provide major conditions for PANoptosis induction. Long-term high glucose can cause mitochondrial dysfunction, triggering oxidative stress and metabolic dysregulation, which then promotes programmed death pathways in podocytes and tubular epithelial cells. [8]
Mitochondria exposed to hyperglycemia produce excess ROS, which can enter the cytosol and activate inflammatory responses. A key mechanism is the activation of the NLRP3 inflammasome in renal cells. [9] The inflammasome is a multiprotein complex composed of NLRP3, caspase-1, and the adaptor ASC. [10] Its activation typically includes two stages:
Priming: High glucose can stimulate Toll-like receptors (TLRs), activating the NF-κB pathway and upregulating expression of NLRP3 and pro-IL-1β. [11]
Activation: Multiple DN-related stimuli-especially mitochondrial ROS and the release of mitochondrial DNA-promote inflammasome assembly. [12]
After assembly, the inflammasome recruits and activates caspase-1, cleaving pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18, thereby driving a robust inflammatory cascade. [13] This inflammatory environment ultimately promotes coordinated activation of apoptosis, pyroptosis, and necroptosis, i.e., PANoptosis. [14] The consequences include podocyte injury (proteinuria), tubular epithelial–mesenchymal transition with fibrosis, and microvascular lesions (microthrombi), collectively accelerating DN deterioration. [15–16]
1.3 PANoptosis directly contributes to proteinuria and fibrosis-signature features of DN
The destructive impact of PANoptosis on podocytes provides a direct mechanistic explanation for proteinuria. Activation of pathways such as TRAIL/DR5 promotes podocyte death, and because podocytes are terminally differentiated, their loss is largely irreversible and compromises the glomerular filtration barrier. In diabetic mouse models, gene deletion of TNFSF10 or TNFRSF10B reduces podocyte PANoptosis and significantly alleviates proteinuria and glomerular injury; conversely, TNFSF10 overexpression worsens these outcomes. Inhibition of the TRAIL/DR5 axis (e.g., siRNA or inhibitors) can reduce TNF-α–stimulated podocyte PANoptosis. [7]
Beyond proteinuria, PANoptosis can promote renal fibrosis through inflammatory cytokine release and fibroblast activation. For example, NLRP3 inflammasome activation in podocytes can release IL-1β and other mediators that contribute to DN inflammation and fibrosis. [18] IL-1β–related signaling (e.g., ROS/NF-κB) can drive lipid accumulation and injury, participating in fibrotic progression. [19] There is also evidence that protection against PANoptosis reduces cytokine release and attenuates fibrosis, emphasizing the importance of PANoptosis-derived inflammatory mediators. [20–21] Podocyte injury can further influence profibrotic signaling networks such as WNT signaling via modulation of factors like WIF1, thereby contributing to fibrosis. [22]

2. From PANoptosis to "Kidney Deficiency with Blood Stasis": A Mechanistic Rationale for the Kidney-Nourishing and Blood-Activating Method
DN involves intricate interactions among cell-death pathways. The TCM theory of "kidney deficiency with blood stasis" emphasizes deficiency leading to stasis and disease entering the collaterals, while PANoptosis offers a contemporary molecular lens. We propose that:
"Spleen–kidney deficiency" (root deficiency) shows functional similarity to mitochondrial energy dysfunction, and
"Phlegm–stasis interlocking" (branch excess) resembles pathological injury patterns driven by NLRP3 inflammasome–mediated inflammatory storms.
Based on this, we propose a testable hypothesis: the kidney-nourishing and blood-activating method may treat DN by modulating PANoptosis, reflecting a "treating both root and branch" strategy-addressing mitochondrial metabolic dysfunction upstream and suppressing NLRP3 inflammasome activation downstream.
2.1 "Spleen–kidney deficiency" and mitochondrial energy metabolism dysfunction: functional similarity
TCM concepts such as "kidney governing transformation" and "spleen governing transport and transformation" can be interpreted as macroscopic descriptions of energy utilization and metabolic regulation. In spleen–kidney deficiency, mitochondrial dysfunction may reduce ATP synthesis and trigger PANoptosis. Clinically, this pattern often manifests as fatigue, reduced vitality, and metabolic sluggishness.
Modern research indicates that declines in spleen–kidney function parallel mitochondrial dysfunction. [23] Mitochondria produce ATP via oxidative phosphorylation and regulate proliferation, metabolism, and cell death. [24] Podocytes and tubular epithelial cells are rich in mitochondria, reflecting their high energy demands for filtration and reabsorption; mitochondria also maintain calcium balance and oxidative stress homeostasis. [25]
Under hyperglycemia, the mitochondrial electron transport chain generates excessive ROS, leading to mtDNA damage, reduced membrane potential, and impaired mitophagy, ultimately causing accumulation of dysfunctional mitochondria. [26–27] Proximal tubular mitochondrial abnormalities can cause ATP deficiency and oxidative damage, driving cellular senescence or apoptosis. [28–29] Thus, hyperglycemia-induced mitochondrial dysfunction (ATP deficit, excessive ROS, mtDNA damage) acts as an initiating event that triggers NLRP3 inflammasome activation and PANoptosis-providing a mechanistic parallel to the TCM notion of impaired transformation and functional decline.
2.2 "Phlegm–stasis interlocking" and NLRP3 inflammasome activation: morphological and pathophysiological alignment
In the "branch excess" aspect of DN, phlegm–stasis interlocking reflects chronic stagnation of fluids and blood, microcirculatory impairment, and progressive fibrosis. Mechanistically, NLRP3 inflammasome activation leads to caspase-1–dependent maturation of IL-1β and IL-18, triggering inflammatory storms. [30] Pyroptosis and other death programs promote renal intrinsic cell death and release of proinflammatory mediators. [31] PANoptosis can thereby remodel the tissue microenvironment, activate fibroblasts, and drive tubulointerstitial fibrosis and microvascular disease. [32]
These pathological features resemble TCM descriptions: "phlegm dampness" corresponding to excessive inflammatory mediators, "blood stasis" to microcirculatory disturbance and fibrosis, and "turbid toxin" to persistent release of damage-associated molecular patterns (DAMPs) such as HMGB1 and ATP, forming a vicious cycle of "cell death → inflammation → further cell death." Certain herbs and bioactives (e.g., berberine) have been reported to inhibit NLRP3 activation and inflammatory polarization processes. [33]
2.3 Hypothesis: the kidney-nourishing and blood-activating method modulates PANoptosis in DN
We therefore propose the following mechanistic axis as a modern interpretation of "kidney deficiency with blood stasis" in DN:
Mitochondrial dysfunction → NLRP3 inflammasome activation → PANoptosis → proteinuria and fibrosis
Accordingly, the kidney-nourishing and blood-activating method (represented by Astragalus–Danshen) may exert therapeutic effects by intervening at multiple nodes of this axis:
"Nourishing" (treating the root): improving mitochondrial energy metabolism (e.g., AMPK/SIRT1/PGC-1α signaling), restoring redox balance, reducing mtROS, thus weakening activation signals for NLRP3;
"Activating blood" (treating the branch): inhibiting NLRP3 inflammasome assembly/activation, scavenging ROS, antagonizing NF-κB–mediated inflammation, blocking caspase-1 activation, thereby suppressing execution of PANoptosis.

3. Evidence from the Astragalus–Danshen Herb Pair Supporting PANoptosis Modulation
TCM offers distinctive advantages in DN prevention and management. Building on the hypothesis above, this section summarizes modern evidence that the Astragalus–Danshen herb pair may protect the kidney via anti-inflammatory, anti-fibrotic, and cytoprotective mechanisms consistent with PANoptosis modulation.
3.1 Astragalus: improving mitochondrial function to suppress upstream triggers of PANoptosis
Astragalus, as a "root-treating" herb, may improve mitochondrial energy metabolism and reduce oxidative stress. Several Astragalus bioactives (e.g., astragaloside IV, Astragalus polysaccharides) are linked to pathways relevant to PANoptosis. [34]
In DN models, astragaloside IV has been reported to attenuate fatty acid–induced renal tubular injury by inhibiting FATP2-mediated fatty acid transport, reducing intratubular lipid accumulation, alleviating mitochondrial dysfunction, lowering mitochondrial ROS, and suppressing downstream NLRP3 activation and IL-18/IL-1β release. This mechanism has been supported in both in vivo (rat) and in vitro (NRK-52E cell) studies. [35]
Astragalus polysaccharides have also been reported to modulate multiple signaling pathways (ASK1, PI3K/AKT, TLR4/NF-κB) and block caspase cascades, protecting against apoptosis. [36] By maintaining mitochondrial homeostasis, regulating apoptosis-related proteins (e.g., Bax, Bcl-2), and reducing ROS accumulation, these components may contribute to mitochondrial protection. [37]
Collectively, Astragalus may reduce key NLRP3 triggering signals (mtROS, mtDNA stress) and suppress PANoptosis initiation upstream.
3.2 Danshen: inhibiting NLRP3 inflammasome activation to block PANoptosis execution
Danshen, a classic "blood-activating" herb, may exert downstream effects by directly targeting inflammasome-related inflammatory programs. Tanshinone IIA has been reported to inhibit oxidative stress–induced pyroptosis via the Txnip/NLRP3 axis, thereby slowing DN progression. [38] Other Danshen constituents, such as salvianolic acid B, show antioxidative properties and may protect mesangial cells through pathways such as SIRT3/FOXO1. [39] Tanshinone IIA has also been reported to reduce high-glucose–induced podocyte injury in vitro [40], and total tanshinones can reduce inflammatory mediator release through pathways including NF-κB. [41]
Overall, Danshen may help block PANoptosis execution by inhibiting NLRP3 inflammasome activation and reducing inflammatory mediator output.
3.3 Synergy and translational relevance: why herbal extracts are sought in DN management
The Astragalus–Danshen combination is not merely additive; it aligns with a multi-node intervention framework for the "mitochondria–NLRP3–PANoptosis" axis. Astragalus may stabilize the intracellular environment by reducing baseline oxidative stress and improving mitochondrial function, enabling Danshen's anti-inflammatory actions to more efficiently suppress NLRP3 inflammasome activity. Conversely, Danshen's rapid inflammasome inhibition may protect mitochondria from secondary inflammatory injury, forming a beneficial feedback loop.
Mechanistically, evidence suggests combined use may synergistically suppress NLRP3-related inflammatory signaling and reduce IL-1β and IL-18 release-key inflammatory mediators closely associated with pyroptosis and broader PANoptosis-related phenotypes. [42] Additionally, Astragalus and Danshen have been reported to alleviate cyclosporin A chronic nephrotoxicity, potentially via anti-inflammatory and anti-apoptotic mechanisms. [43]
From a real-world perspective, many patients seek herbal extracts for diabetes and kidney health for understandable reasons: chronic disease burden, long treatment horizons, concern about polypharmacy, and an interest in "natural" supportive approaches. However, mechanistic plausibility must be matched with rigorous verification (omics, cell-specific knockouts, and clinically measurable biomarkers) and safety oversight.
4. Integrating Cistanche (Cistanche tubulosa) into the Mechanistic Landscape of DN Support (Hypothesis-Level Discussion)
Cistanche (Rou Cong Rong) is a well-known TCM tonic herb traditionally associated with "kidney tonification." A commercial product page describing Cistanche tubulosa extract lists key constituents such as echinacoside, verbascoside (acteoside), total phenylethanoid glycosides, and flavonoids, and presents it as a kidney-support oriented supplement, with suggested oral use and a daily amount of 3–5 g for adults.
WECISTANCHE-CistancheKidney Page
From a mechanistic standpoint-without claiming clinical efficacy for DN-Cistanche's reported antioxidant and anti-fatigue positioning, together with phenylethanoid glycosides and flavonoids, makes it a plausible candidate for exploration within the upstream portion of the proposed axis (mitochondrial dysfunction → oxidative stress → inflammasome activation). citeWECISTANCHE-CistancheKidneyPage
Research implication: Future studies could examine whether Cistanche extracts or specific constituents (e.g., echinacoside/verbascoside) modulate:
mitochondrial ROS generation and mitophagy quality control,
NF-κB priming of inflammasome components,
NLRP3 inflammasome assembly, and
PANoptosome-related nodes (e.g., caspase-8 integration).
This would position Cistanche within an evidence-building framework relevant to "Herb Extract for Diabetes Kidney Support," while preserving scientific validity and clinical caution.

5. Summary and Outlook
This article, grounded in the cutting-edge concept of PANoptosis, proposes and preliminarily elaborates the hypothesis that the kidney-nourishing and blood-activating method may treat DN by modulating the PANoptosis network. It provides a potential modern biological interpretation for the TCM theory of "kidney deficiency with blood stasis," centered on a candidate pathogenic axis: mitochondrial dysfunction → NLRP3 inflammasome activation → PANoptosis.
Using Astragalus–Danshen as an example, we summarize a multi-target evidence chain across molecular, cellular, and animal studies supporting roles in mitochondrial repair, oxidative stress reduction, and inflammasome inhibition-mechanisms consistent with suppressing PANoptosis. Nonetheless, limitations remain:
Direct experimental evidence explicitly addressing PANoptosome formation and regulation in DN is still limited; many studies focus on single pathways.
Mechanistic causality requires robust validation using cell-specific gene-editing models (e.g., podocyte-specific NLRP3 knockout) and pathway-level probes to determine whether herbs or constituents directly target PANoptosome components such as NLRP3 and caspase-8.
Clinical translational evidence remains weak; many trials have limited sample size and lack direct measurement of PANoptosis-specific biomarkers (e.g., co-localization of phosphorylated MLKL and GSDMD-N) in renal tissue or serum.
Future work should integrate gene-edited models, multi-omics mapping of regulatory networks, and biomarker-driven clinical studies to establish an evidence chain connecting herbal interventions, PANoptosis modulation, and meaningful renal outcomes.
References
[1] Abhirami B L, Krishna A A, Kumaran A, et al. Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents. Archives of Pharmacal Research. 2025;48(7–8):577–637.
[2] DeFronzo R A, Reeves W B, Awad A S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nature Reviews Nephrology. 2021;17(5):319–334.
[3] Jiang L, Zhao L, Liu Y, et al. PANoptosis: A novel therapeutic target in kidney disease (Review). International Journal of Molecular Medicine. 2025;56(6):207.
[4] Dai X, Liao R, Liu C, et al. Epigenetic regulation of TXNIP-mediated oxidative stress and NLRP3 inflammasome activation contributes to SAHH inhibition-aggravated diabetic nephropathy. Redox Biology. 2021;45:102033.
[5] Zhang Daning. Research on the TCM Method of Kidney-Nourishing and Blood-Activating. Beijing: China Medical Science and Technology Press; 1997.
[6] Zhuang S, Li F, Wang L, et al. Neutrophil extracellular trap-derived double-stranded RNA aggravates PANoptosis in renal ischemia reperfusion injury. Cell Communication and Signaling. 2025;23(1):140.
[7] Lv Z, Hu J, Su H, et al. TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease. Kidney International. 2025;107(2):317–331.
[8] Zhang K, Wu D, Huang C. Crosstalk between non-coding RNA and apoptotic signaling in diabetic nephropathy. Biochemical Pharmacology. 2024;230(Pt 3):116621.
[9] Liu X, Zhou D, Su Y, et al. PDIA4 targets IRE1α/sXBP1 to alleviate NLRP3 inflammasome activation and renal tubular injury in diabetic kidney disease. BBA - Molecular Basis of Disease. 2025;1871(3):167645.
[10] Liao C, Xu F, Yu Z, et al. The Novel Role of the NLRP3 Inflammasome in Mycotoxin-Induced Toxicological Mechanisms. Veterinary Sciences. 2024;11(7):291.
[11] Su W J, Li J M, Zhang T, et al. Microglial NLRP3 inflammasome activation mediates diabetes-induced depression-like behavior via triggering neuroinflammation. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2023;126:110796.
[12] Li H, Yang X, Song Y, et al. PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress. Veterinary Microbiology. 2023;279:109673.
[13] Yang M, Zhao L. The Selective NLRP3-Inflammasome Inhibitor CY-09 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3-inflammasome activation. Current Medicinal Chemistry. 2023;30(28):3261–3270.
[14] Oda K, Miyamoto S, Kodera R, et al. Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice. Journal of Diabetes Investigation. 2023;14(2):205–220.
[15] Cao Y, Hu L, Chen R, et al. Unfolded protein response-activated NLRP3 inflammasome contributes to pyroptotic and apoptotic podocyte injury in diabetic kidney disease via the CHOP-TXNIP axis. Cellular Signalling. 2025;130:111702.
[16] Han W, Chen S, Ma B, et al. Cordycepin ameliorates high glucose-induced proliferation, inflammation, and extracellular matrix deposition in glomerular mesangial cells through Smad7-dependent manner. Molecular Immunology. 2025;183:156–171.
[17] Matoba K, Takeda Y, Nagai Y, et al. ROCK2-induced metabolic rewiring in diabetic podocytopathy. Communications Biology. 2022;5(1):341.
[18] Lassen E, Bouchareb R, Daehn I S. Podocyte as the link between sterile inflammation and diabetic kidney disease. Kidney International. 2022;102(4):688–690.
[19] Wu M, Yang Z, Zhang C, et al. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Metabolism. 2021;118:154748.
[20] Duan S, Li X, Han J, et al. Transcriptotype-driven discovery of Apigenin as a therapy against cholestatic liver fibrosis: through inhibition of PANoptosis and following type-I interferon responses. Antioxidants (Basel). 2024;13(3):256.
[21] Liu Q, Niu Y, Pei Z, et al. Gas6-AXL signal promotes indoor VOCs exposure-induced pulmonary fibrosis via pulmonary microvascular endothelial cells-fibroblasts cross-talk. Journal of Hazardous Materials. 2024;474:134786.
[22] Sun H, Li H, Yan J, et al. Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease. Nature Communications. 2022;13(1):1600.
[23] Gao Juan, Huang Yumei, Chen Liwei, et al. Exploring mechanisms of treating neonatal hypoxic–ischemic brain injury from the spleen–kidney perspective based on mitochondrial dysfunction. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2025;34(4):542–546.
[24] Andrieux P, Chevillard C, Cunha-Neto E, et al. Mitochondria as a cellular hub in infection and inflammation. International Journal of Molecular Sciences. 2021;22(21):11338.
[25] Thompson A D, Victor Santiago R P, Scholpa N E, et al. Repurposing mitochondria-targeted therapeutics for kidney diseases. Kidney International. 2025;107(4):617–627.
[26] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling. Annals of Translational Medicine. 2023;11(2):41.
[27] Zhang Z, Huang Q, Zhao D, et al. The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications. Frontiers in Endocrinology. 2023;14:1112363.
[28] Zhou S, Ling X, Meng P, et al. Cannabinoid receptor 2 plays a central role in renal tubular mitochondrial dysfunction and kidney ageing. Journal of Cellular and Molecular Medicine. 2021;25(18):8957–8972.
[29] Yang K, Li T, Geng Y, et al. The role of mitophagy in the development of chronic kidney disease. PeerJ. 2024;12:e17260.
[30] Islamuddin M, Qin X. Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics. Cell Death Discovery. 2024;10(1):229.
[31] Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cellular & Molecular Immunology. 2021;18(9):2114–2127.
[32] Fu H, Gu Y H, Tan J, et al. CircACTR2 in macrophages promotes renal fibrosis by activating macrophage inflammation and epithelial–mesenchymal transition of renal tubular epithelial cells. Cellular and Molecular Life Sciences. 2022;79(5):253.
[33] Sun J, Zeng Q, Wu Z, et al. Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration. Neurotherapeutics. 2024;21(4):e00347.
[34] Ni Songlin, Wang Mengyue, Sun Mo, et al. Research progress of Astragalus in preventing and treating heart failure based on PANoptosis. Chinese Journal of Experimental Traditional Medical Formulae. 2025;31(17):276–284.
[35] Wang J, Wang L, Feng X, et al. Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2. Phytomedicine. 2024;134:155991.
[36] Li M, Han B, Zhao H, et al. Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases. Phytomedicine. 2022;98:153918.
[37] Yuan Q, Yuan Y, Zheng Y, et al. Anti-cerebral ischemia reperfusion injury of polysaccharides: a review of the mechanisms. Biomedicine & Pharmacotherapy. 2021;137:111303.
[38] Wu Q, Guan Y B, Zhang K J, et al. Tanshinone IIA mediates protection from diabetes kidney disease by inhibiting oxidative stress induced pyroptosis. Journal of Ethnopharmacology. 2023;316:116667.
[39] Wen F, Zhang S, Sun L, et al. Salvianolic Acid B inhibits oxidative stress in glomerular mesangial cells alleviating diabetic nephropathy by regulating SIRT3/FOXO1 signaling. Kidney & Blood Pressure Research. 2023;48(1):738–751.
[40] Zhu S, Kang Z, Zhang F. Tanshinone IIA suppresses ferroptosis to attenuate renal podocyte injury in diabetic nephropathy through ELAVL1 and ACSL4 signaling. Journal of Diabetes Investigation. 2024;15(8):1003–1016.
[41] Li X, Qiu H, Gan J, et al. Total tanshinones protect against acute lung injury through the PLCγ2/NLRP3 inflammasome signaling pathway. Journal of Ethnopharmacology. 2023;314:116478.
[42] Zhang Z, Chen F, Wan J, et al. Potential traditional Chinese medicines with anti-inflammation in the prevention of heart failure following myocardial infarction. Chinese Medicine. 2023;18(1):28.
[43] Gao R R, Han C, Sui G Y, et al. Huangqi and Danshen improve the chronic nephrotoxicity of cyclosporin A by regulating lipid metabolism. Phytomedicine. 2025;140:156582.
Web source (product/ingredient & usage information)
WECISTANCHE. China Cistanche for Kidney disease Suppliers, Manufacturers, Factory - Wholesale Price - WECISTANCHE (Cistanche tubulosa extract; ingredients, form, suggested usage, dosage 3–5 g/day, etc.). citeWECISTANCHE-CistancheKidneyPage






